BioMed Research International

Review Article

Molecular Imaging in Traditional Chinese Medicine Therapy for Neurological Diseases

Table 2

Molecular imaging in traditional Chinese medicine therapy for neurological disease.


Disease models	CHM type	Drug or acupoints	Tracers	Modality	Functional outcome	References

MCAO (rats)	CHM	ASG IV-TMPZ	¹⁸F-FDG	PET	Enhanced functional recovery and glucose metabolism	[31]
MCAO (rats)	CHM	CXQ-PUE	¹⁸F-FDG	PET	Recovery glucose metabolism, reduced infarction volume	[32]
MCAO (rats)	CHM	BAI-JAS	NULL	DWI-MRI	Enhanced cerebral ischemia injury repair	[34]
MCAO (rats)	ACU	DU14, 20 LI10, ST36	NULL	DTI-MRI	Improved neurons regeneration	[35]
WD (human)	ACU	Du20, 23, EXH- N3, PC6, Sp6	NULL	DTI-MRI	Improved functional recovery	[36]
Stroke (human)	ACU	LI 14, LI11	NULL	fMRI	Enhanced functional recovery	[37]
Stroke (human)	CHM	CG	NULL	T2W-MRI	Ameliorated brain edema	[38]
MCAO (rats)	ACU	GV20	NULL	DWI-MRI	Alleviated brain oedema	[39]
MCAO (rats)	ACU	GV20, GV26	¹⁸F-FDG	DWI-MRI and PET	Improved metabolic recovery, reduced the injuryvolume	[40]
AD (mice)	CHM	Evodiamine	¹⁸F-FDG	PET/CT	Improved glucose uptake and cognitive abilities	[41]
AD (rats)	CHM	Fuzhisan	¹⁸F-FDG	PET	Ameliorated glucose metabolism of brain	[42]
AD (human)	CHM	Fuzhisan	¹⁸F-FDG	PET	Increased rCMRglc	[43]
AD (human)	ACU	ST36, 40, HT7, KI3	NULL	fMRI	Improved cognitive function	[44]
AD (human)	ACU	Liv3, LI4	NULL	fMRI	Enhanced cognitive recovery	[45]
PD (human)	ACU	MS4, 6, 9, 14	¹⁸F-FDG	PET	Improve cerebral glucose metabolism	[46]
PD (human)	ACU	MS4, 6, 8, 9, 14	^99mTc-E, ^9mTc-T4	SPECT	Increased rCBF	[47]
PD (mice)	ACU	PC 7	¹²³I-IBZM	SPECT	Attenuated neuronal damage	[48]

MCAO: middle cerebral artery occlusion; WD: wallerian degeneration; AD: Alzheimer’s disease; PD: Parkinson’s disease; CHM: Chinese herb medicine; ACU: acupuncture; ASG IV: Astragaloside IV; TMPZ: tetramethylpyrazine; CXQ-PUE: chuanxiongzine and puerarin; BAI-JAS: baicalin and jasminoidin; DU20: Baihui; DU14: Dazhui; LI10: Shousanli; ST36: Zusanli; Du 23: Shangxin; EXHN3: Yintang; PC6: Neiguan; Sp6: Sanyingjiao; LI11: Quch; LI14: Binao; CG: cerebralcare granule; GV20: Baihu; GV26: Shuigou; HT7: Shenmen; ST36: Zusanii; ST40; Fenglong; KI3: Taixi; Liv3: Taichong; LI4: Hegu; MS6: the anterior oblique meridian of the vertex to temple; MS4: the lateral III meridian on forehead; MS8: the lateral I meridian of the vertex; MS9: the lateral II meridian of the vertex; MS14: lower-lateral meridian of the occiput; MS8: the lateral I meridian of the vertex; PC: Daling; [¹⁸F] FDG: 2-deoxy-2-(¹⁸F)fluoro-D-glucose; ^99mTc-E ^99mTc-ECD: technetium-99m ethyl cysteinate dimer; ^99mTc-T4: ^99mTc-TRODAT-4; [¹²³I] IBZM: ¹²³I-iodobenzamide; rCMRglc: regional cerebral metabolic rate of glucose consumption; rCBF: regional cerebral blood flow.